Lecture 23 - Parkinson's Disease Flashcards

1
Q

What are the clinical symptoms of Parkinson’s disease?

A
1. Motor
 • Slowness
 • Stiffness
 • Tremor
 • Postural instability
 • Stooped, shuffling gait
 • Decreased arm swing when walking
 • Swallowing difficulty
 • Immobile facial expressions
2. Cognitive
 • Mood changes
 • Depression
 • Anxiety
 • Pain
 • Tiredness
 • Confusion
3. Sensory
 • Numbness
 • Aching
 • Pain
 • Anosmia
  1. Autonomic
    • Hot/cold sensations
    • Constipation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is lost in PD?

A

Substantia nigra dopaminergic neurons in midbrain

Specifically:
• Ventrolateral area of SN
• i.e. the part where the neurons that extend to the striatum are

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

At what point does PD present?

A

60-70% of SN dopamineragic cells are lost

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the function of the SN?

A
  • Control of voluntary movement

* Production of dopamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the function of dopamine?

A
  • Regulation of mood

* Planning and modulation of movement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Where is the SN?

A

In the midbrain

Part of the basal ganglia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the basal ganglia?

What is it made up of?

A
Collection of nuclei in the white matter of the cerebral cortex
Made up of nuclei:
 • Striatum: 
- Putamen
- Caudate nucleus
 • Globus pallidus
 • SN:
- Pars reticulate
- Pars compacta
• Subthalamic nuclei
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the two parts of the SN?

Which is affected in PD?

A

Pars compacta
Pars reticulata

Pars compacta is made up of the large pigmented neurons that project to the striatum
These are the neurons that are affected

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the connectivity of the SN

A

Dopaminergic neurons project to striatum

Release dopamine onto these neurons → control of movement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What causes PD?

A
1. Sporadic / idiopathic
 • the majority
Suggested mediators:
 • Toxins (such as pesticides)
 • Metals
 • certain drugs e.g. MPTP, a recreational drug
2. Familial
Number of genes identified:
 • α-synuclein (SNCA)
 • Parkin
 • Leucine rich repeat kinase
 • DJ-I
 • PINK1
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What pathological features are typical of PD?

A

Lewy bodies:
• Intracellular inclusions of protein

Lewy neurites
• similar to Lewy bodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the composition of Lewy bodies?

A

α-synuclein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is important about the structure of α-synuclein?

A

Natively unfolded

Basic domain:
• Rich in basic amino acids
α-helical formation

TM domain:
• Hydrophobic region

Acidic domain:
• mainly negatively charged

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the function of α-synuclein?

A
Linked to:
 • Learning
 • Development
 • Synaptic plasticity
 • Regulation of vesicular transport & dopamine release
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

When does Lewy body accumulation start?

A

Proposed that it is well before diagnosis
Normally starts to accumulate outside the SN
Only diagnosed once accumulating in the SN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Which factors modulate the aggregation of α-synuclein?

i.e., what promotes and what inhibits aggregation?

A
Promotion:
 • α-syn over-expression
 • mutation in α-syn
 • Fe
 • Oxidants
 • Environmental toxins

Inhibition:
• Dopamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the role of α-synuclein and metals?

A

Metals can promote the aggregation of α-synuclein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the interaction between α-synuclein and dopamine?

A

Dopamine induce α-synuclein oligomers are not Thioflavin T reactive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Describe the α-synuclein aggregation pathways with and without dopamine

A
  1. W/o dopamine:
    α-syn monomer → α-syn oligomer → insoluble α-syn fibrils (ThT positive) → Lewy bodies
  2. W/ dopamine:
    α-syn monomer → soluble α-syn oligomers (ThT negative)
20
Q

What is the inheritance of α-synuclein mutation?

A

Dominantly inherited

21
Q

What happens in α-synuclein mutation?

Describe how this could lead to disease

A

Copy number variation: duplication & triplication of the gene
→ Over-expression of α-synuclein

Increased α-synuclein concentration promotes aggregation

22
Q

What mouse models have been used to study PD?

A
  1. Mutant human α-synuclein
  2. Over-expression of wild type α-synuclein
  3. Intracerebral α-syuclein inoculation
23
Q

What is observed in mice with mutant human α-synuclein?

What is the significance of this?

A

• Lewy bodies in brain
• Motor deficit
→ Substantiates the theory that α-synuclein causes motor deficits in PD in humans

24
Q

What is observed in mice with over-expression of wild type α-synuclein?

A
  • Lewy body formation
  • Reduced striatal tyrosine hydroxylase levels (→ decreased dopamine)
  • Movement disorder: less time spent on rotorod
25
Q

Describe the propagation of α-synuclein observed in mice studies

What is the significance of this?

A

When α-synuclein is inoculated intracerebrally, there is rapid, progressive neurodegeneration observed

This study was done in mice

Mutant α-synuclein from symptomatic mouse injected into non-symptomatic mouse:
• Reduced life span
• Spreading of α-synuclein from area of injection to other regions

→ Indicated that α-synuclein spreads and propagates throughout the brain once present in PD
This may be what is seen in the Braak staging

26
Q

Describe the cellular release and uptake of α-synuclein

A
  • Through secretory vesicles
  • Multi-vesicular bodies → released in exosomes
  • Recycling endosome: release contents out into extracellular space

The neurons are not dying, but rather are viable

One neurone can deposit α-synuclein into the extracellular space (monomeric or aggregated) and it can be taken up by other cells
e.g.
• Astrocytes take it up → inflammation
• Taken up by other neighbouring neurons → propagation

27
Q

Is Parkin mutation a significant cause of Parkinsonism?

A

2nd most common genetic cause of Parkinsonism

28
Q

What is the function of Parkin?

What is the proposed role in PD?

What type of mutation is it: loss / gain of function ?

A

• Cytosolic protein
• Role in clearance of protein:
- cellular ubiquitination / protein degradation pathway
• i.e. it acts as ubiquitin ligase

Role in PD
 • Loss of Parkin
 • Non-ubiquitinated substrates accumulating in neurons
 • Altered protein turn-over
→ SN degeneration

• Autosomal recessive, loss of function mutations

29
Q

What is the function of PINK1?

What is the proposed role in PD?

A

Normal function:
• Phosphorylation of TRAP1
• TRAP1 is a mitochondrial chaperone protein

Increased phosphorylation of TRAP1 under oxidative stress

In PD:
• Mutations leads to loss of kinase activity

30
Q
Compare the inheritance of the following:
 • SNCA
 • Parkin
 • PINK1
 • LRRK2
 • DJ-1
A

SNCA: Autosomal dominant

Parkin: Autosomal-recessive

PINK1: Autosomal recessive

LRRK2: Autosomal dominant

DJ-1: Autosomal recessive

31
Q

What is the function of LRRK2?

What is the proposed role in PD?

A

Precise function unknown
• Role in intracellular signalling? (its kinase domain is of the MAPKKK class)
• Promotion of mitochondrial & golgi fragmentation

PD:
• Mutation → Increased kinase activity
• Increased mitochondrial and golgi fragmentation

32
Q

What is the function of DJ-1?

What is the proposed role in PD?

A

Function:
• Unknown
• Involved in modulating the oxidative stress response and mitochondrial function
• Oxidative stress → DJ-1 translocated to outer mitochondrial membrane

In PD:
• Unknown

33
Q

Describe the causal spectrum of PD

A

Familial ←————→ Sporadic
Genetic variants ←–→ Environment

The more dominant the genetic variant, the less role the environmental needs to play

34
Q

Describe the interaction of the mitochondria and α-synuclein

A

α-synuclein interacts with and inhibits Complex I of ETC
→ fragmentation
→ neuronal death

PINK1, DJ-1 and Parkin all interact with the mitochondria
Mutation in the genes for these proteins can lead to mitochondria dysfunction
→ Energy loss from cell
→ Cell death

35
Q

Is the presence of Lewy bodies diagnostic for PD?

A

No

36
Q

What is Braak staging?

A

Stages of PD based on where the Lewy bodies are deposited
6 stages

Location of Lewy bodies:
Stage 1: in dorsal motor nucleus of vagal nerve
→ olfactory structures

Stage 2: Lower raphe nuclei
→ stress and panic responses

Stage 3: SN
→ clinical diagnosis

Stage 4: temporal mesocortex
→ memory and emotions

Stage 5: temporal neocortex
→ memory and language

Stage 6: Neocortex
→ primary sensory areas

Progressive deposition of Lewy bodies
Location of deposition relates to the clinical features seen at that time

37
Q

What is the significance of Thioflavin T reactive material?

A

Signifies aggregation of α-synuclein into amyloid plaques

38
Q

What is the effect of dopamine on pre-formed, insoluble α-synuclein fibrils?

A

Can reverse the aggregation and make it soluble

39
Q

What is the effect of point mutation in the gene for α-synuclein?

A

Alters the aggregating properties

For example:
• Aggregates more quickly (shortened lag phase)
• Reaches a high level of aggregation

40
Q

What is the function of tyrosine hydroxylase?

What is the significance?

A

Enzyme for synthesis of dopamine

In transgenic mice that were over-experssing α-synuclein:
• Reduced levels of this enzyme
→ Reduced dopamine

41
Q

Describe the propagation of recombinant α-synuclein

A

Recombinant :
from bacteria, i.e. has never been in a brain before

When the recombinant α-synuclein was injected into asymptomatic, non-transgenic mice it spread to other regions

42
Q

Describe the change in life span observed in mice injected with mutant α-synuclein brain lysate

A

Injected mice: die at around 280 days
• If injected very early (at birth) there is even sooner onset of death

Non-injected mice: around 470 days

Injection of the brain lysate reduces the life span of the transgenic mice

43
Q

In homozygous Parkin mutation, what is the age of onset of PD?

A

10-50 years: i.e. juvenile PD

44
Q

What is the age of onset of sporadic PD?

A

70-80 years

Later than the familial causes

45
Q

Describe the role of glucoscerebroside in PD

A

Glucoscerebroside stabilises α-synuclein oligomers

Normally it is broken down into ceremide in lysosomes

Mutations in the protein that break down glucoscerebroside lead to increased α-synuclein aggregation

46
Q

What factors intracellularly can lead to α-synuclein aggregation?

A
  • Parkin: decreased protein degradation
  • LRRK2: Golgi fragmentation
  • Glucoscerebroside: stabilisation of α-synuclein oligomers
  • LRRK2: Mitochondria fragmentation → energy loss from cells